Cardiff Lexington CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQX
Cardiff Lexington Corporation reported a significant net loss and negative operating cash flow for 2024, raising substantial doubt about its ability to continue as a going concern, despite securing an increased line of credit.
OQX
Cardiff Lexington Corporation's 2024 10-K filing highlights a strategic focus on healthcare acquisitions amidst financial challenges, including operating losses and a going concern warning.
OQX
10-K/A: Cardiff Lexington Corporation Files Amended 10-K After SEC Comments, Reports Improved Financials
Cardiff Lexington Corporation files an amendment to its 2023 annual report to address SEC comments, highlighting a shift to profitability and growth in its healthcare segment.
OQX
Cardiff Lexington Corporation has filed an amendment to its 2023 annual report to include the correct independent auditor's report and exhibit.
OQX
Cardiff Lexington Corporation files an amendment to its 2023 annual report to address SEC comments, with no other changes to the original filing.
OQX
Cardiff Lexington Corporation files a certificate of correction for Series B, C, E, F-1, I, and L preferred stock and reports a net income of $3.03 million for 2023, a significant turnaround from a net loss in 2022.